Chronic Heart Failure with Preserved Systolic Function: the Features of Morphological and Functional Status of Platelets and Their Changes under the Influence of the Treatment

O.V. Kuryata, Yu.S. Kushnir


Chronic heart failure (CHF) is one of the main problems of cardiovascular diseases. In recent years views on CHF structure have changed — CHF with preserved systolic function of the left ventricle is prevailed. The risk of thrombosis persists despite the use of aspirin, that requires changes in the tactics of treatment. We aimed to examine the morphological and functional status of platelets in patients with CHF and preserved ejection fraction associated with coronary heart disease (CHD) and changes when using meldonium in a complex therapy against administration of aspirin. The study included 12 patients (8 males, 4 females) aged from 51 to 75 years (mean age, М ± m, 67.8 ± 2.7 years) with CHF of functional class II and III, who had preserved systolic function of the left ventricle, associated with CHD. Control group consisted of 6 patients with CHD aged from 46 to 61 years ((mean age 50.8 ± 2.2 years) without clinical and objective data of CHF. All examined patients with CHF were divided into 2 groups depending on the type of treatment. The first group included 7 patients with CHF, who in addition to standard therapy recieved meldonium (Vazopro preparation, produced by Farmak, Ukraine) in the dose of 1.0 g intravenously. The second group included 5 patients who received only standard therapy. The morphological and functional status of platelets was estimated by electronic microscopy. In CHF there had been detected an increase in platelet aggregation, suggesting an increased risk of thrombosis in these patients. The use of meldonium in comprehensive treatment of CHF determine not only for the positive clinical effect, but the effect of the platelets by reducing the number of activated, aggregated, degranulated and increase of non-activated forms.


chronic heart failure; platelets; meldonium


Влияние милдроната в составе комбинированной терапии хронической сердечной недостаточности у больных сахарным диабетом 2-го типа на углеводный, липидный обмен и показатели оксидативного стресса / М.Е. Стаценко, С.В. Туркина, С.В. Беленкова [и др.] // Рос. кардиол. журнал. — 2010. — № 2(82). — С. 45-51.

Коркушко О.В. Тромбоциты: физиология, морфология, возрастные и патологические особенности, антитромбоцитарная терапия / О.В. Коркушко, В.Ю. Лишневская. — К.: Медкнига, 2011. — 240 с.

Михин В.П. Роль кардиоцитопротекторов в терапии хронической сердечной недостаточности ишемического генеза / В.П. Михин, В.В. Савельева // Рос. кардиол. журнал. — 2009. — № 1(75). — С. 49-56.

Наказ МОЗ України від 03.07.2006 р. № 436. Протокол надання медичної допомоги хворим із хронічною серцевою недостатністю.

Перцева Н.О. Кількісна ультраструктурна характеристика тромбоцитів у хворих на цукровий діабет 2-го типу у фазі компенсації з артеріальною гіпертонією за умов корекції артеріального тиску лозартаном / Н.О. Перцева // Морфологія. — 2011. — T. V, № 4. — С. 37-44.

Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН / И.В. Фомин, Ю.Н. Беленков, В.Ю. Мареев и др. // Сердечная недостаточность. — 2006. — Т. 7, № 3. — С. 112-115.

Сиволап В.В. Антитромбоцитарная терапия и хроническая сердечная недостаточность / В.В. Сиволап // Внутренняя медицина. — 2007. — Т. 6. — С. 15-18.

A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial «MILSS I» / Vilnis Dzerve, MILSS I Study Group // Medicina (Kaunas). — 2011. — 47(10). — Р. 544-551.

Forstеrmann U. Endothelial nitric oxide synthase in vascular disease: from marvel to menace / U. Forstermann, T. Munzell // Circulation. — 2006. — Vol. 113. — P. 1708-1714.

McMurray J. The burden of heart failure / J. McMurray, S. Stewart // Eur. Heart J. — 2003. — Vol. 5 (Suppl. 1). — P. 13-113.

Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial / V. Dzerve, D. Matisone, Y. Pozdnyakov, R. Oganov // Seminars in Cardiovascular Medicine. — 2010. — 16(3). — P. 1-8.

Schafer A. Rapid regulation of platelet activation in vivo by nitric oxide / A. Schafer, F. Wiesmann, S. Neubauer // Circulation. — 2004. — Vol. 109. — P. 1819-1822.

Task Force Members. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005) // Eur. Heart J. — 2005. — Vol. 26. — P. 1115-1140.

The epidemiology of heart failure: the Framingham Study / K.K. Ho, J.L. Pinsky, W.B. Kannel, D. Levy // JACC. — 1993. — Vol. 22. — P. 6-13.

Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта